Catalyst Wire Dossier Catalyst Wire Dossier

Zalypsis

PM00104 · PharmaMar
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Zalypsis, covering 2021-07-28 to 2021-10-29. Get the full timeline:

Most recent: Clinical Trial Update: Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy [Phase 2]

See pricing